519 related articles for article (PubMed ID: 35811293)
21. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
22. Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Rajwa P; Yanagisawa T; Heidegger I; Zattoni F; Marra G; Soeterik TFW; van den Bergh RCN; Valerio M; Ceci F; Kesch CV; Kasivisvanathan V; Laukhtina E; Kawada T; Nyiriadi P; Trinh QD; Chlosta P; Karakiewicz PI; Ploussard G; Briganti A; Montorsi F; Shariat SF; Gandaglia G;
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):170-179. PubMed ID: 36284192
[TBL] [Abstract][Full Text] [Related]
23. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Mutlu H; Bozcuk H
J Cancer Res Ther; 2023; 19(2):394-402. PubMed ID: 37313915
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
25. Upfront Androgen Receptor-Axis-Targeted Therapies in Men with De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer.
Kimura N; Kaneko Y; Tetsuka T; Takei A; Uchida T; Abe H; Amiya Y; Shima T; Suzuki N; Hayashi S; Nakatsu H
Urol J; 2023 Jul; 20(4):222-228. PubMed ID: 36906797
[TBL] [Abstract][Full Text] [Related]
26. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
Sathianathen NJ; Koschel S; Thangasamy IA; Teh J; Alghazo O; Butcher G; Howard H; Kapoor J; Lawrentschuk N; Siva S; Azad A; Tran B; Bolton D; Murphy DG
Eur Urol; 2020 Mar; 77(3):365-372. PubMed ID: 31679970
[TBL] [Abstract][Full Text] [Related]
27. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis.
Jian T; Zhan Y; Hu K; He L; Chen S; Hu R; Lu J
Front Pharmacol; 2022; 13():955925. PubMed ID: 36278154
[No Abstract] [Full Text] [Related]
28. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
Mori K; Mostafaei H; Sari Motlagh R; Pradere B; Quhal F; Laukhtina E; Schuettfort VM; Kramer G; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
BJU Int; 2022 Apr; 129(4):423-433. PubMed ID: 34171173
[TBL] [Abstract][Full Text] [Related]
29. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
[TBL] [Abstract][Full Text] [Related]
30. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Vale CL; Fisher DJ; White IR; Carpenter JR; Burdett S; Clarke NW; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Rydzewska LH; Sweeney CJ; Spears MR; Sydes MR; Tierney JF
Ann Oncol; 2018 May; 29(5):1249-1257. PubMed ID: 29788164
[TBL] [Abstract][Full Text] [Related]
31. Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.
Wala J; Nguyen P; Pomerantz M
J Clin Oncol; 2023 Jul; 41(20):3584-3590. PubMed ID: 37267579
[No Abstract] [Full Text] [Related]
32. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
33. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
[TBL] [Abstract][Full Text] [Related]
34. Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
Lee A
Target Oncol; 2023 Sep; 18(5):793-800. PubMed ID: 37542594
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?
Sanmamed N; Gómez-Rivas J; Buchser D; Montijano M; Gómez-Aparicio MA; Duque-Santana V; Torres L; Zilli T; Ost P; Maldonado A; López-Campos F; Couñago F
Clin Genitourin Cancer; 2024 Feb; 22(1):56-66. PubMed ID: 37599133
[TBL] [Abstract][Full Text] [Related]
36. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic.
Stecca CE; Jiang DM; Veitch Z; Hotte SJ; Alimohamed N; Wood L; Sridhar SS
Clin Genitourin Cancer; 2023 Apr; 21(2):273-277. PubMed ID: 36621461
[TBL] [Abstract][Full Text] [Related]
38. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Rajwa P; Pradere B; Gandaglia G; van den Bergh RCN; Tsaur I; Shim SR; Yanagisawa T; Laukhtina E; Mori K; Mostafaei H; Quhal F; Bryniarski P; Compérat E; Roubaud G; Massard C; Merseburger AS; Leapman MS; Spratt DE; Saad F; Joniau S; D'Amico AV; Briganti A; Shariat SF; Ploussard G;
Eur Urol; 2022 Jul; 82(1):82-96. PubMed ID: 35465985
[TBL] [Abstract][Full Text] [Related]
39. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
Liu M; Qu S; Liu Y; Yao X; Jiang W
J Comp Eff Res; 2019 Aug; 8(11):865-877. PubMed ID: 31476895
[No Abstract] [Full Text] [Related]
40. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.
Riaz IB; Naqvi SAA; He H; Asghar N; Siddiqi R; Liu H; Singh P; Childs DS; Ravi P; Hussain SA; Murad MH; Boorjian SA; Sweeney C; Van Allen EM; Bryce AH
JAMA Oncol; 2023 May; 9(5):635-645. PubMed ID: 36862387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]